---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109119"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:15:00.915739+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Capricor reports Q3 net loss $24.6M; HOPE-3 topline DMD data expected in Q4 2025

## Summary
- Net loss of $24.6M ($0.54/share) vs $12.6M ($0.38) in Q3 2024; operating expenses $26.3M, up 72%.
- Revenue $0 vs $2.3M in prior year; prior revenue from Nippon Shinyaku milestones now fully recognized.
- Cash $98.6M as of Sept 30, down from $151.5M at Dec 31, 2024; runway into Q4 2026.
- Topline results from HOPE-3 Phase 3 trial of Deramiocel for Duchenne cardiomyopathy expected in Q4 2025.
- FDA supported submitting HOPE-3 results for BLA resubmission (Type A meeting); PLI completed with all 483 observations addressed.

## SEC filing metadata
- accession: 0001104659-25-109119
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/0001104659-25-109119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109119
- JSON: https://secwatch.observer/filing/0001104659-25-109119.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.